ArticleOpen heart2026
Prognostic value of stress perfusion cardiac magnetic resonance in patients with known or suspected coronary artery disease and supranormal left ventricular ejection fraction.
Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrior studies have shown that a supranormal range of left ventricular ejection fraction (LVEF) is associated with adverse cardiovascular outcomes. However, the prognostic value of stress perfusion cardiac magnetic resonance (CMR) in patients with supranormal LVEF is not well defined. This study aimed to assess the prognostic significance of stress perfusion CMR in patients with known or suspected coronary artery disease and supranormal LVEF.
methodsThis cohort study included patients aged ≥18 years who underwent clinical stress perfusion CMR at an academic hospital in Thailand between 2011 and 2022 and had an LVEF ≥65% on CMR. Patients were divided into two groups based on the presence of myocardial ischaemia on CMR and were followed for major adverse cardiovascular events (MACE), defined as a composite of all-cause death, acute coronary syndrome (ACS) or hospitalisation for heart failure.
resultsA total of 531 patients were included (mean age 68.7±11.0 years; 42.6% male; mean LVEF 75.1%±6.2%). Myocardial ischaemia was detected in 124 patients. During a median follow-up of 5.4 years (IQR, 2.1-9.5), 63 MACE occurred. Patients with myocardial ischaemia had a significantly higher rate of MACE than those without ischaemia (3.71 vs 1.74 per 100 patient-years; HR 2.13; 95% CI 1.28 to 3.54; p=0.004). In multivariable Cox regression analysis, myocardial ischaemia remained independently associated with MACE (HR 1.81; 95% CI 1.08 to 3.05; p=0.02). The prognostic value of myocardial ischaemia was consistent across LVEF tertiles (p for interaction=0.79). Other independent predictors included age (HR 1.03; 95% CI 1.001 to 1.05; p=0.03), a history of heart failure (HR 2.65; 95% CI 1.57 to 4.46; p<0.001) and LV mass index (HR 1.03; 95% CI 1.02 to 1.04; p<0.001).
conclusionsIn patients undergoing stress perfusion CMR with supranormal LVEF, myocardial ischaemia detected by CMR provided significant prognostic value for predicting a composite of all-cause death, ACS or hospitalisation for heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.